Select Your Region
Global
A Study to Evaluate the Effects of Basmisanil in Participants With Cognitive Impairment Associated With Schizophrenia (CIAS) Treated With Antipsychotics
- Psychiatric Disorder
- Schizophrenia
Please note that the recruitment status of the trial at your site may differ from the overall study status because some study sites may recruit earlier than others.
Trial Status:
Completed
This trial runs in
Cities
- Bellevue
- Berlin
- Boston
- Cedarhurst
- Cleveland
- Culver City
- Dayton
- Decatur
- Gaithersburg
- Garden Grove
- Glendale
- Hoffman Estates
- Irving
- Largo
- Lauderhill
- Little Rock
- Maitland
- Miami
- National City
- New Haven
- New York
- North Canton
- Oakland
- Orange
- Pico Rivera
- Richardson
- Rochester
- Rogers
- San Diego
- Shreveport
- St. Louis
- Torrance
Trial Identifier:
NCT02953639 BP39207
Trial Summary
This multicenter study assessed the effects of 24 weeks of basmisanil treatment on cognition and functioning of stable schizophrenia participants treated with antipsychotics.
Hoffmann-La Roche
Sponsor
Phase 2
Phase
NCT02953639,BP39207
Trial Identifier
Basmisanil, Placebo
Treatments
Schizophrenia
Condition
Official Title
A Phase IIb, Multicenter, Randomized, Double-Blind, Parallel Group, Placebo Controlled Study to Evaluate the Efficacy, Safety and Tolerability of Basmisanil (RO5186582) as Adjunctive Treatment in Patients With Cognitive Impairment Associated With Schizophrenia Treated With Antipsychotics
Eligibility Criteria
All
Gender
≥ 18 Years & ≤ 50 Years
Age
No
Healthy Volunteers
Inclusion Criteria
- Diagnosis of schizophrenia of any type utilizing the Mini International Neuropsychiatric Interview and diagnostic and statistical manual of mental disorders, fifth edition (DSM-5) direct clinical assessments, family informants and past medical records
- Evidence of stability of symptoms for 3 months at screening, that is, without hospitalizations for schizophrenia or increase in level of psychiatric care due to worsening of symptoms of schizophrenia
- Participants with schizophrenia clinical symptom severity defined by the following: hallucinatory behavior item score less than or equal to (</=) 5 and a delusion item score </= 5 of the PANSS
- Participants on a stable regimen of antipsychotic therapy for at least 3 months at screening and receiving no more than two antipsychotics
Exclusion Criteria
- Participants with current DSM-5 diagnosis other than schizophrenia including bipolar disorder, schizoaffective disorder and major depressive disorder
- Clinically significant neurological illness or significant head trauma that affects cognitive function, in the judgment of the principal investigator
- Full scale intelligence quotient </=65 on the Wechsler Abbreviated Scale of Intelligence at screening
- Positive result at screening for hepatitis B, hepatitis C, or human immunodeficiency virus-1 and 2
- Moderate to severe substance use disorder (other than nicotine or caffeine), as defined by the DSM-5, within the last 12 months
- Suicide attempt within 1 year or currently at risk of suicide in the opinion of the Investigator
For the latest version of this information please go to www.forpatients.roche.com